Head-to-head evidence
Ipratropium vs Tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Ipratropium
Developed by Boehringer Ingelheim
NCT06074185 · Phase 2 · completed
The study was not randomized or blinded and compared patients treated before and after implementation of the bundle rather than using a concurrent controlled trial; the intervention also included dexamethasone and a checklist, so the effect cannot be attributed to ipratropium alone. Although hospital admission is a clinical endpoint, the primary comparison was based on a small and internally inconsistent set of reported participants, with no reported significance analysis, so the result is unclear.
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT00772538 · Phase 3 · completed
The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.
Next expected readout: January 2027 · NCT06679465 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ipratropium's landscape · Tiotropium bromide's landscape